-- 据彭博社周四援引公司和业内消息人士报道，Meta Platforms (META) 首席执行官马克·扎克伯格和苹果公司 (AAPL) 首席执行官蒂姆·库克并未计划竞购美国国家橄榄球联盟 (NFL) 的西雅图海鹰队。 报道称，Meta 的一位发言人表示，扎克伯格没有对该球队进行任何投资或竞购，而一位熟悉库克计划的人士则否认了他参与此事。 Meta 和苹果公司均未立即回复的置评请求。 （市场闲谈新闻来源于与全球市场专业人士的对话。这些信息据信来自可靠来源，但可能包含传闻和猜测。准确性无法保证。）
Price: $616.43, Change: $-52.69, Percent Change: -7.87%
Toronto-Dominion Bank (TD.TO) after the close Thursday said it issued its seventh sustainable-labelled bonds for 150-million Swiss francs. The bank said its total sustainable bond issuances have now exceeded C$5.2 billion since 2014."TD's first European green bond continues building the strength of our sustainable financing program, helping us support clients pursuing sustainable investment in a new jurisdiction," said Nicole Vadori, head of sustainability at TD.TD shares closed up $3.40 at $146.33 on Toronto Stock Exchange.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Amgen delivered solid Q1 2026 results with revenues of $8.6B (+6% Y/Y), $50M above consensus, and non-GAAP EPS of $5.15 (+5% Y/Y), beating expectations by $0.38. The company demonstrated continued execution of its portfolio diversification strategy, with sixteen products achieving double-digit growth and seventeen products annualizing above $1B. We favorably view AMGN's broad-based growth across newer therapeutic franchises, with standout performances from Repatha (+34% Y/Y), TEPEZZA (+29% Y/Y), and TEZSPIRE (+20% Y/Y), offsetting expected declines in legacy products facing biosimilar competition. Management raised 2026 guidance to $37.1B-$38.5B in revenues and EPS of $21.70-$23.10. R&D expenses surged 16% Y/Y to $1.7B, reflecting intensive investments in the MariTide obesity program and multiple Phase 3 studies. We believe AMGN's successful portfolio transformation and strategic focus on high-growth therapeutic areas position it well for sustained long-term growth.